Controlling the cost of breast cancer

European Journal of Cancer Care

Volumn 20, Issue 6, 2011, Pages 703-707

  Gill, D ^a   Bruce, D ^a   Tan, P H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Cost; Economics

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; NATIONAL HEALTH SERVICE; REVIEW; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; STATE MEDICINE;

EID: 80054093912     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2011.01289.x     Document Type: Review

References (27)

1. Baxevanis C. & Papamichail M. (1994) Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Critical Reviews in Oncology/Hematology 16, 157-179.
2. Cancer Research UK (2010) ' Breast Cancer - The facts' (online). Available at: (last accessed 25 May 2011).
3. Clemons M.J., Dranitsaris G., Ooi W.S., Yogendran G., Sukovic T., Wong B.Y.L., Verma S., Pritchard K.I., Trudeau M. & Cole D.E.C. (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Journal of Clinical Oncology 24, 4895-4900.
4. Colleoni M. & Maibach R. (2007) BIG 1-07/1BCSG 35-07 SOLE ready for activation. Breast International Group Newsletter 9, 22.
5. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nole F., Peruzzotti G., Robertson C., Orlando L., Cinieri S., De Braud F., Viale G. & Goldhirsch A. (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Annals of Oncology 13, 73-80.
6. Department of Health (2010) Estimated England Level Gross Expenditure by Programme Budget (online). Available at: (last accessed 25 May 2011).
7. Goetz M., Knox S., Suman V., Rae J., Safgren S., Ames M., Visscher D., Reynolds C., Couch F., Lingle W., Weinshilboum R., Fritcher E., Nibbe A., Desta Z., Nguyen A., Flockhart D., Perez E. & Ingle J. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. 113-121.
8. Joensuu H., Kellokumpu-Lehtinen P., Bono P., Alanko T., Kataja V., Asola R., Utriainen T., Kokko R., Hemminki A., Tarkkanen M., Turpeenniemi-Hujanen T., Jyrkkio S., Flander M., Helle L., Ingalsuo S., Johansson K., Jaaskelainen A., Pajunen M., Rauhala M., Kaleva-Kerola J., Salminen T., Leinonen M., Elomaa I., Isola J. & Finher Study I. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England Journal of Medicine 354, 809-820.
9. Joint Formulary Committee (2010) British National Formulary, 59th edn. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK.
10. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Revil C. & Jones A. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of Clinical Oncology 27, 5529-5537.
11. Kelly C.M., Juurlink D.N., Gomes T., Duong-Hua M., Pritchard K.I., Austin P.C. & Paszat L.F. (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. British Medical Journal 340, c693.
12. McCowan C., Shearer J., Donnan P.T., Dewar J.A., Crilly M., Thompson A.M. & Fahey T.P. (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. British Journal of Cancer 99, 1763-1768.
13. Neyt M., Huybrechts M., Hulstaert F., Vrijens F. & Ramaekers D. (2008) Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 87, 146-159.
14. NHS Breast Cancer Screening Programmes (2011) How Much does the Breast Screening Programme Cost. Available at: (last accessed 17 July 2011).
15. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Wickerham D.L. & Wolmark N. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734.
16. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F. & Slamon D. (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241-2251.
17. Perez E.A., Romond E.H., Suman V.J., Jeong J., Davidson N.E., Geyer C.E., Martino S., Mamounas E.P., Kauffman P.A., Wolmark N. & NCCTG/NSABP (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical Oncology (Meeting Abstracts) 25, 512.
18. Raftery J. (2009) NICE and the challenge of cancer drugs. British Medical Journal 338, b67.
19. Ratain M.J. & Cohen E.E. (2007) The value meal: how to save $1700 per month or more on Lapatinib. Journal of Clinical Oncol 25, 3397-3398.
20. Regional Drug and Therapeutics Centre (2008) Which Bisphosphonate for Osteopososis. Available at: (last accessed 17 July 2011).
21. The King's Fund (2011) Exploring Variations in Primary Care Trusts' Spending on Cancer Services. Available at: (last accessed 17 July 2011).
22. Towse A. (2009) Should NICE's threshold range for cost per QALY be raised? Yes. British Medical Journal 338, b181.
23. Turaga K., Acs G. & Laronga C. (2010) Gene expression profiling in breast cancer. Cancer Control 17, 177-182.
24. Untch M., Muscholl M., Tjulandin S., Jonat W., Meerpohl H.-G., Lichinitser M., Manikhas A.G., Coumbos A., Kreienberg R., Du Bois A., Harbeck N., Jackisch C., Muller V., Pauschinger M., Thomssen C., Lehle M., Catalani O. & Luck H.-J. (2010) First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. Journal of Clinical Oncology 28, 1473-1480.
25. Warren J.L., Yabroff K.R., Meekins A., Topor M., Lamont E.B. & Brown M.L. (2008) Evaluation of trends in the cost of initial cancer treatment. Journal of the National Cancer Institute 100, 888-897.
26. Wolff A.C., Hammond M.E.H., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., Van De Vijver M., Wheeler T.M. & Hayes D.F. (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25, 118-145.
27. Wolowacz S.E., Cameron D.A., Tate H.C. & Bagust A. (2008) Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. Journal of Clinical Oncology 26, 925-933.